Achieving definitive results by analyzing the entire human genome.

The SYMPHONY™ signature development process began by identifying two groups of women: those who had a recurrence within five years following surgery and those who were cancer free at five years. The entire human genome of 25,000 genes was analyzed for both groups, and the resulting differences in gene expression were captured. What’s more significant, is that none of the women in either group were treated with either chemo or hormonal therapy. This control process allowed the pure biology of the tumors to be followed for more than 20 years — ultimately ensuring a definitive, actionable result for each of your patients.